Delaware
|
|
20-0077155
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification No.)
|
Title
of Each
Class
of Securities
To
Be
Registered
|
Amount
To
Be
Registered
(1)
|
Proposed
Maximum
Offering
Price
Per
Share
|
Proposed
Maximum
Aggregate
Offering
Price
|
Amount
of
Registration
Fee
|
|||||||||
Common
Stock, par value $0.005 per share
|
45,000
(2
|
)
|
$
|
6.00
(3
|
)
|
$
|
270,000.00
|
$
|
28.89
|
||||
Common
Stock, par value $0.005 per share
|
1,955,000
(4
|
)
|
$
|
7.48
(5
|
)
|
$
|
14,623,400.00
|
$
|
1,564.70
|
||||
Total
|
2,000,000
|
--
|
$
|
14,893,400.00
|
$
|
1,593.59
|
(1)
|
This
registration statement shall also cover any additional shares of
Common
Stock of the Registrant that may become issuable under the employee
benefits plan being registered pursuant to this registration statement
by
reason of any stock dividend, stock split, recapitalization or any
other
similar transaction, effected as required by such plans.
|
(2)
|
Represents
shares of Common Stock subject to options outstanding under the Cleveland
BioLabs, Inc. 2006 Equity Incentive Plan.
|
(3)
|
Computed
in accordance with Rule 457(h) of the Securities Act of 1933, as
amended.
The offering price of $6.00 represents the exercise price of all
options
outstanding under the Cleveland BioLabs, Inc. 2006 Equity Incentive
Plan.
|
(4)
|
Represents
shares of Common Stock reserved for issuance under the Cleveland
BioLabs,
Inc. 2006 Equity Incentive Plan.
|
(5)
|
Computed
in accordance with Rule 457(h) of the Securities Act of 1933, as
amended.
The offering price of $7.48 represents the average of the high and
low
prices, as reported on the NASDAQ Capital Market, for Cleveland BioLabs,
Inc.’s Common Stock on February 8,
2007.
|
Plan
Information.*
|
Registrant
Information and Employee Plan Annual Information.*
|
*
|
The
documents containing the information specified in Part I of Form
S-8 have
been or will be sent or given to employees as specified by Rule 428(b)(1)
of the Securities Act of 1933, as amended (the “Securities Act”).
|
Incorporation
of Documents by Reference.
|
Description
of Securities.
|
Interests
of Named Experts and Counsel.
|
Indemnification
of Directors and Officers.
|
Exemption
From Registration Claimed.
|
Exhibits.
|
No.
|
Description
|
||
3.1
|
|
Certificate
of Incorporation of Cleveland BioLabs, Inc.*
|
|
3.2
|
|
Certificate
of Amendment of Certificate of Incorporation of Cleveland BioLabs,
Inc.*
|
|
3.3
|
|
Second
Certificate of Amendment of Certificate of Incorporation of Cleveland
BioLabs, Inc.*
|
|
3.4
|
|
Amended
and Restated By-Laws of Cleveland BioLabs, Inc.*
|
|
4.1
|
|
Cleveland
BioLabs, Inc. 2006 Equity Incentive Plan*
|
|
4.2
|
|
Form
of Specimen Stock Certificate**
|
|
5.1
|
|
Opinion
of Katten Muchin Rosenman LLP
|
|
23.1
|
|
Consent
of Katten Muchin Rosenman LLP (included in Exhibit 5.1)
|
|
23.2
|
|
Consent
of Meaden & Moore, Ltd.
|
|
24.1
|
|
Power
of Attorney (included on the signature page to this registration
statement)
|
|
*
|
Incorporated
by reference to Amendment No. 3 to Registration Statement on Form
SB-2 as
filed on July 10, 2006 (File No. 333-131918).
|
**
|
Incorporated
by reference to Amendment No. 1 to Registration Statement on Form
SB-2 as
filed on April 25, 2006 (File No. 333-131918).
|
Undertakings.
|
CLEVELAND
BIOLABS, INC.
|
||
|
|
|
By: | /s/ MICHAEL FONSTEIN | |
Name:
Michael Fonstein
Title:
Chief Executive Officer & President
|
||
Signature
|
|
Title
|
|
Date
|
/
S
/ Michael Fonstein
|
|
Chief
Executive Officer, President, and Director (Principal Executive
Officer)
|
|
February
13, 2007
|
Michael
Fonstein
|
||||
/
S
/ John A. Marhofer Jr.
|
|
Chief
Financial Officer (Principal Financial and Accounting
Officer)
|
|
February
13, 2007
|
John
A. Marhofer Jr.
|
||||
/
S
/ James Antal
|
|
Director
|
|
February
13, 2007
|
James
Antal
|
||||
/
S
/ Paul DiCorleto
|
|
Director
|
|
February
13, 2007
|
Paul
DiCorleto
|
||||
/
S
/ Andrei Gudkov
|
|
Chief
Scientific Officer, and Director
|
|
February
13, 2007
|
Andrei
Gudkov
|
||||
/
S
/ Bernard L. Kasten
|
|
Director
|
|
February
13, 2007
|
Bernard
L. Kasten
|
||||
/
S
/ Yakov Kogan
|
|
Executive
Vice President, and Director
|
|
February
13, 2007
|
Yakov
Kogan
|
||||
/
S
/ H. Daniel Perez
|
|
Director
|
|
February
13, 2007
|
H.
Daniel Perez
|
Exhibit
No.
|
Description | ||
3.1
|
|
Certificate
of Incorporation of Cleveland BioLabs, Inc.*
|
|
3.2
|
|
Certificate
of Amendment of Certificate of Incorporation of Cleveland BioLabs,
Inc.*
|
|
3.3
|
|
Second
Certificate of Amendment of Certificate of Incorporation of Cleveland
BioLabs, Inc.*
|
|
3.4
|
|
Amended
and Restated By-Laws of Cleveland BioLabs, Inc.*
|
|
4.1
|
|
Cleveland
BioLabs, Inc. 2006 Equity Incentive Plan*
|
|
4.2
|
|
Form
of Specimen Stock Certificate**
|
|
5.1
|
|
Opinion
of Katten Muchin Rosenman LLP
|
|
23.1
|
|
Consent
of Katten Muchin Rosenman LLP (included in Exhibit 5.1)
|
|
23.2
|
|
Consent
of Meaden & Moore, Ltd.
|
|
24.1
|
|
Power
of Attorney (included on the signature page to this registration
statement)
|
|
*
|
Incorporated
by reference to Amendment No. 3 to Registration Statement on Form
SB-2 as
filed on July 10, 2006 (File No. 333-131918).
|
**
|
Incorporated
by reference to Amendment No. 1 to Registration Statement on Form
SB-2 as
filed on April 25, 2006 (File No. 333-131918).
|